StockNews.com began coverage on shares of Cara Therapeutics (NASDAQ:CARA – Free Report) in a research report sent to investors on Monday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Cara Therapeutics Stock Up 7.4 %
Shares of CARA stock opened at $0.31 on Monday. The firm has a market cap of $16.97 million, a price-to-earnings ratio of -0.13 and a beta of 0.70. Cara Therapeutics has a 12 month low of $0.24 and a 12 month high of $1.40. The stock has a 50-day moving average price of $0.29 and a 200 day moving average price of $0.43.
Cara Therapeutics (NASDAQ:CARA – Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.10). The business had revenue of $0.99 million for the quarter, compared to the consensus estimate of $1.26 million. Cara Therapeutics had a negative return on equity of 241.31% and a negative net margin of 1,010.20%. Sell-side analysts predict that Cara Therapeutics will post -1.24 earnings per share for the current fiscal year.
Institutional Trading of Cara Therapeutics
About Cara Therapeutics
Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.
Featured Articles
- Five stocks we like better than Cara Therapeutics
- What to Know About Investing in Penny Stocks
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- Consumer Discretionary Stocks Explained
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.